{"id":353354,"date":"2010-02-23T11:24:45","date_gmt":"2010-02-23T16:24:45","guid":{"rendered":"http:\/\/www.xconomy.com\/?p=64682"},"modified":"2010-02-23T11:24:45","modified_gmt":"2010-02-23T16:24:45","slug":"genocea-gets-uw-hutch-patents","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/353354","title":{"rendered":"Genocea Gets UW, Hutch Patents"},"content":{"rendered":"\n<div style=\"text-transform:uppercase\"><a href=\"http:\/\/www.xconomy.com\/tag\/Biotech\/\">Biotech<\/a>, <a href=\"http:\/\/www.xconomy.com\/tag\/vaccines\/\">vaccines<\/a>, <a href=\"http:\/\/www.xconomy.com\/tag\/startups\/\">startups<\/a><\/div>\n<p>\t\t<strong>Luke Timmerman wrote:<\/strong><\/p>\n<p>Genocea Biosciences, a Cambridge, MA-based vaccine developer, <a href=\"http:\/\/www.businesswire.com\/portal\/site\/home\/permalink\/?ndmViewId=news_view&amp;newsId=20100223005105&amp;newsLang=en\">said today<\/a> it has obtained licenses to 25 pending or issued patents on herpes simplex type 2 antigens from the University of Washington and Fred Hutchinson Cancer Research Center. Those antigens could be used as\u00a0 the basis for a new immune-boosting treatment for genital herpes. Genocea CEO Staph Bakali described the company&#8217;s plans to treat herpes <a href=\"http:\/\/www.xconomy.com\/boston\/2009\/12\/22\/genocea-eyes-vaccines-that-treat-not-just-prevent-infectious-diseases\/\">in an interview with Xconomy in December<\/a>.<\/p>\n<div class=\"postFooter\"><a href=\"http:\/\/www.xconomy.com\/seattle\/2010\/02\/23\/genocea-gets-uw-hutch-patents\/#comments\">Comments<\/a> | <a href=http:\/\/www.xconomy.com\/reprints\/>Reprints<\/a> | Share: &nbsp;<br \/>\n<a href=\"http:\/\/twitter.com\/home?status=RT%20@Xconomy%20Genocea%20Gets%20UW,%20Hutch%20Patents%20http:\/\/xconomy.com\/?p=64682\"  rel=\"nofollow\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/twitter.gif\" alt=\"Retweet\"\/><\/a><br \/>\n&nbsp;<a href=\"http:\/\/www.facebook.com\/sharer.php?u=http:\/\/www.xconomy.com\/seattle\/2010\/02\/23\/genocea-gets-uw-hutch-patents\/&#038;t=Genocea%20Gets%20UW,%20Hutch%20Patents\"  rel=\"nofollow\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/facebook.gif\" alt=\"Facebook\"\/><\/a><br \/>\n&nbsp;<a href=http:\/\/www.xconomy.com\/seattle\/2010\/02\/23\/genocea-gets-uw-hutch-patents\/email\/  rel=\"nofollow\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/email.gif\" alt=\"Email\"\/><\/a><br \/>\n&nbsp;<a href=\"http:\/\/sharethis.com\/item?publisher=bfda184d-6684-4f7a-a23f-ca4ed4db9287&amp;title=Genocea+Gets+UW%2C+Hutch+Patents&amp;url=http%3A%2F%2Fwww.xconomy.com%2Fseattle%2F2010%2F02%2F23%2Fgenocea-gets-uw-hutch-patents%2F\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/share.gif\" alt=\"Share\"\/><\/a>\n<\/div>\n<p>\t     \t\t<br clear=\"both\" style=\"clear: both;\"\/><br \/>\n<br clear=\"both\" style=\"clear: both;\"\/><br \/>\n<a href=\"http:\/\/ads.pheedo.com\/click.phdo?s=01893e4eeaae9e9cb3575de7a18f84a4&#038;p=1\"><img decoding=\"async\" alt=\"\" style=\"border: 0;\" border=\"0\" src=\"http:\/\/ads.pheedo.com\/img.phdo?s=01893e4eeaae9e9cb3575de7a18f84a4&#038;p=1\"\/><\/a><br \/>\n<img loading=\"lazy\" decoding=\"async\" alt=\"\" height=\"0\" width=\"0\" border=\"0\" style=\"display:none\" src=\"http:\/\/a.rfihub.com\/eus.gif?eui=2218\"\/><\/p>\n<p><a href=\"http:\/\/feedads.g.doubleclick.net\/~a\/9KZAoaEB7kZBdLUXKZBEP29R-9o\/0\/da\"><img decoding=\"async\" src=\"http:\/\/feedads.g.doubleclick.net\/~a\/9KZAoaEB7kZBdLUXKZBEP29R-9o\/0\/di\" border=\"0\" ismap=\"true\"><\/img><\/a><br \/>\n<a href=\"http:\/\/feedads.g.doubleclick.net\/~a\/9KZAoaEB7kZBdLUXKZBEP29R-9o\/1\/da\"><img decoding=\"async\" src=\"http:\/\/feedads.g.doubleclick.net\/~a\/9KZAoaEB7kZBdLUXKZBEP29R-9o\/1\/di\" border=\"0\" ismap=\"true\"><\/img><\/a><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~r\/Xconomy_Full\/~4\/iY3PqIQaU-E\" height=\"1\" width=\"1\"\/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Biotech, vaccines, startups Luke Timmerman wrote: Genocea Biosciences, a Cambridge, MA-based vaccine developer, said today it has obtained licenses to 25 pending or issued patents on herpes simplex type 2 antigens from the University of Washington and Fred Hutchinson Cancer Research Center. Those antigens could be used as\u00a0 the basis for a new immune-boosting treatment [&hellip;]<\/p>\n","protected":false},"author":1192,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-353354","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/353354","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/1192"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=353354"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/353354\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=353354"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=353354"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=353354"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}